Log in
OTCMKTS:GNWSF

StageZero Life Sciences Stock Forecast, Price & News

$0.57
+0.02 (+3.66 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.57
Now: $0.57
$0.57
50-Day Range
$0.05
MA: $0.52
$0.77
52-Week Range
$0.17
Now: $0.57
$0.89
Volume27,046 shs
Average Volume5,359 shs
Market Capitalization$27.70 million
P/E RatioN/A
Dividend YieldN/A
Beta2.97
StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNWSF
CUSIPN/A
CIKN/A
Phone905-209-2030
Employees16

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$140,000.00
Book Value($0.13) per share

Profitability

Net Income$-3,480,000.00

Miscellaneous

Market Cap$27.70 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$0.57
+0.02 (+3.66 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNWSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNWSF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











StageZero Life Sciences (OTCMKTS:GNWSF) Frequently Asked Questions

How has StageZero Life Sciences' stock price been impacted by COVID-19 (Coronavirus)?

StageZero Life Sciences' stock was trading at $0.0266 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GNWSF shares have increased by 2,027.8% and is now trading at $0.5660.
View which stocks have been most impacted by COVID-19
.

When is StageZero Life Sciences' next earnings date?

StageZero Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for StageZero Life Sciences
.

Who are some of StageZero Life Sciences' key competitors?

Who are StageZero Life Sciences' key executives?

StageZero Life Sciences' management team includes the following people:
  • Mr. James R. Howard-Tripp, Exec. Chairman & CEO
  • Mr. Carl Solomon, Interim Chief Financial Officer
  • Prof. Choong-Chin Liew, Co-Founder
  • Mr. Warren Whitehead C.M.A., Chief Accountant (Age 68)
  • Mr. David Suria, Sr. Scientist

What is StageZero Life Sciences' stock symbol?

StageZero Life Sciences trades on the OTCMKTS under the ticker symbol "GNWSF."

How do I buy shares of StageZero Life Sciences?

Shares of GNWSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is StageZero Life Sciences' stock price today?

One share of GNWSF stock can currently be purchased for approximately $0.57.

How big of a company is StageZero Life Sciences?

StageZero Life Sciences has a market capitalization of $27.70 million and generates $140,000.00 in revenue each year. StageZero Life Sciences employs 16 workers across the globe.

What is StageZero Life Sciences' official website?

The official website for StageZero Life Sciences is www.stagezerolifesciences.com.

How can I contact StageZero Life Sciences?

StageZero Life Sciences' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The company can be reached via phone at 905-209-2030 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.